Zydus, Daewoong Pharmaceutical collaborate for development and commercialisation of Leuprolide Acetate for Depot Suspension
Zydus Worldwide DMCC, a subsidiary of Zydus Lifesciences Ltd and Daewoong Pharmaceutical on Monday announced that they have entered into an exclusive licensing agreement to co-develop and commercialize Leuprolide Acetate for Depot Suspension (RLD: Lupron Depot®, AbbVie) in six dosage strengths for the United States market.
Zydus, Daewoong Pharmaceutical collaborate for development and commercialisation of Leuprolide Acetate for Depot Suspension Read More